For advanced NSCLC patients with EGFR mutations, especially exon 19 deletions, EGFR tyrosine kinase inhibitors were associated with better OS compared with conventional chemotherapy based on most studies including the phase III IPASS trial comparing gefitinib with doublet chemotherapy in the first-line setting29,30. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.